Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vanda (VNDA) and Regeneron (REGN)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vanda (NASDAQ:VNDA) and Regeneron (NASDAQ:REGN).

Vanda (VNDA)

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Vanda today. The company’s shares opened today at $19.69.

Archila noted:

“We reiterate our Buy rating and $30 target price. All relevant disclosures and certifications appear on pages 3 – 5 of this report. Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.Investment Thesis We believe Vanda’s current valuation is an attractive entry point for investors, given its accelerating base business and relatively de-risked, late-stage pipeline that we believe is under-appreciated.”

According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -11.1% and a 27.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vanda with a $27.17 average price target, implying a 38.0% upside from current levels. In a report issued on October 16, Citigroup also maintained a Buy rating on the stock with a $31 price target.

.

See today’s analyst top recommended stocks >>

Regeneron (REGN)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Regeneron today and set a price target of $385. The company’s shares opened today at $344.82.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 7.0% and a 46.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $407.42 average price target, implying a 18.2% upside from current levels. In a report issued on October 16, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $419 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts